Previous
Next
40+
integrated databases
90,000+
users worldwide
20M+
curated findings
5,000+
new data findings/day
1,600,000+
patient tests analyzed
Expert curated genomic and clinical knowledge, together with bioinformatics software and services, for actionable insights
Accelerated Decisions
Access over 40 genomic, clinical and pharmaceutical databases updated weekly by hundreds of expert curators.
Deeper Insights
Enrich your NGS analysis and interpretations with cutting-edge bioinformatics software solutions trusted by thousands worldwide.
Better Outcomes
Make improvements in life possible by partnering with one bioinformatics software provider empowering you from Sample to Insight.
Products from Bench to Bedside
Previous
Next
Sample to Insight
DNA Panel Testing
Targeted NGS panels and optimized analysis and interpretation bioinformatics software tools.
Consulting Services for Extending your Insights
Research Bioinformatics Services
Discovery Bioinformatics Services is a reliable and convenient way to extend your in-house resources with expertise and perfectly tailored bioinformatics software and services that ensure high-quality results.
Pharmaceutical Development Services
Enabling pharma companies to develop biomarker diagnostics and targeted therapies using real-world insights from oncology patient genomic data.
Clinical Analysis & Interpretation Services
Helping clinical testing laboratories leverage the benefits of automation and expert support to improve test turnaround times, enhance clinical reporting capabilities and scale for future growth.
Web Seminars and Events
Join us at an event or attend a web seminar to learn how our products, solutions and services are empowering customers around the world to unlock valuable molecular insights.
Read our Case Studies
Case Study 1
Çukurova University in Adana, Turkey, analyzes the ancient origins of rare genetic diseases
Case Study 2
Scientists at the University of Washington develop new Ebola model and find clues to genetics of host resistance
Case Study 3
Mount Sinai identifies a novel prognostic biomarker associated with treatement response in ovarian cancer patients